Editorial: How Will Aducanumab Approval Impact AD Research?

J Prev Alzheimers Dis. 2021;8(4):391-392. doi: 10.14283/jpad.2021.46.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Alzheimer Disease / drug therapy*
  • Amyloid / pharmacology
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Cognitive Dysfunction / prevention & control
  • Disease Progression
  • Drug Approval*
  • Humans
  • Research*

Substances

  • Amyloid
  • Antibodies, Monoclonal, Humanized
  • aducanumab